Elevated suppressor of cytokine signaling-1 (SOCS-1): A mechanism for dysregulated osteoclastogenesis in HIV transgenic rats

Pathogens and Disease

Volumn 71, Issue 1, 2014, Pages 81-89

  Lafferty, Mark K ^a   Fantry, Lori ^a   Bryant, Joseph ^a   Jones, Odell ^a   Hammoud, Dima ^b   Weitzmann, M Neale ^c,d   Lewis, George K ^a   Garzino Demo, Alfredo ^a   Reid, William ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

HIV 1; Osteoclast; Osteoporosis; SOCS 1

Indexed keywords

GAMMA INTERFERON; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SUPPRESSOR OF CYTOKINE SIGNALING 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; CYTOKINE; SOCS1 PROTEIN, RAT; SUPPRESSOR OF CYTOKINE SIGNALING;

ANIMAL CELL; ARTICLE; BONE DENSITY; BONE METABOLISM; CELL DIFFERENTIATION; CONTROLLED STUDY; FRACTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RAT; TRANSGENIC RAT; ANIMAL; BIOSYNTHESIS; BONE DISEASES, METABOLIC; CELL CULTURE; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BONE DISEASES, METABOLIC; CELLS, CULTURED; CYTOKINES; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; OSTEOCLASTS; RATS, TRANSGENIC; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84901974897     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12117     Document Type: Article

References (63)

1. Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, Neit-Ngeilh L, Rozenbaum W & De Vernejoul MC (2004) BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19: 402-409.
2. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM & Suda T (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190: 1741-1754.
3. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD & Reid IR (2007) Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clin Endocrinol 67: 270-275.
4. Boyle WJ, Simonet WS & Lacey DL (2003) Osteoclast differentiation and activation. Nature 423: 337-342.
5. Brown TT & Qaqish RB (2007) Response to Berg et al. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 21: 1830-1831.
6. Carr A, Miller J, Eisman JA & Cooper DA (2001) Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 15: 703-709.
7. Clerici M & Shearer GM (1993) A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 14: 107-111.
8. Dalpke AH, Eckerle S, Frey M & Heeg K (2003) Triggering of Toll-like receptors modulates IFN-gamma signaling: involvement of serine 727 STAT1 phosphorylation and suppressors of cytokine signaling. Eur J Immunol 33: 1776-1787.
9. Deeks SG (2009) Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 17: 118-123.
10. Dolan SE, Kanter JR & Grinspoon S (2006) Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 91: 2938-2945.
11. Fakruddin JM & Laurence J (2003) HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 278: 48251-48258.
12. Fakruddin JM & Laurence J (2005) HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 150: 67-78.
13. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN & Pacifici R (2007) IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 117: 122-132.
14. Gibellini D, Borderi M, De Crignis E, Cicola R, Vescini F, Caudarella R, Chiodo F & Re MC (2007) RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol 79: 1446-1454.
15. Haskelberg H, Carr A & Emery S (2011) Bone turnover markers in HIV disease. AIDS Rev 13: 240-250.
16. Hayashi T, Kaneda T, Toyama Y, Kumegawa M & Hakeda Y (2002) Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. J Biol Chem 277: 27880-27886.
17. Hu X & Ivashkiv LB (2009) Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31: 539-550.
18. Ji JD, Park-Min KH, Shen Z, Fajardo RJ, Goldring SR, McHugh KP & Ivashkiv LB (2009) Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J Immunol 183: 7223-7233.
19. Kamolmatyakul S, Chen W & Li YP (2001) Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation. J Dent Res 80: 351-355.
20. Kong YY, Feige U, Sarosi I et al. (1999a) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309.
21. Kong YY, Yoshida H, Sarosi I et al. (1999b) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
22. Kotake S, Udagawa N, Takahashi N et al. (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103: 1345-1352.
23. Lacey DL, Timms E, Tan HL et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
24. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP & Teitelbaum SL (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106: 1481-1488.
25. Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP & Weitzmann MN (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109: 3839-3848.
26. Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A & Mura MS (2004) Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 48: 39-48.
27. Manolagas SC & Jilka RL (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332: 305-311.
28. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, Aldrovandi GM, Cardoso SW, Santana JL & Brown TT (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 51: 937-946.
29. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M & Tebas P (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36: 482-490.
30. Nakashima T & Takayanagi H (2008) The dynamic interplay between osteoclasts and the immune system. Arch Biochem Biophys 473: 166-171.
31. Nakashima T, Hayashi M, Fukunaga T et al. (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17: 1231-1234.
32. Nolan D, Upton R, McKinnon E, John M, James I, Adler B, Roff G, Vasikaran S & Mallal S (2001) Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 15: 1275-1280.
33. Ofotokun I & Weitzmann MN (2010) HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes 17: 523-529.
34. Ohishi M, Matsumura Y, Aki D, Mashima R, Taniguchi K, Kobayashi T, Kukita T, Iwamoto Y & Yoshimura A (2005) Suppressors of cytokine signaling-1 and -3 regulate osteoclastogenesis in the presence of inflammatory cytokines. J Immunol 174: 3024-3031.
35. Paton NI, Macallan DC, Griffin GE & Pazianas M (1997) Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 61: 30-32.
36. Prior J, Burdge D, Maan E, Milner R, Hankins C, Klein M & Walmsley S (2007) Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 18: 1345-1353.
37. Reid W, Sadowska M, Denaro F et al. (2001) An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. P Natl Acad Sci USA 98: 9271-9276.
38. Reid W, Abdelwahab S, Sadowska M, Huso D, Neal A, Ahearn A, Bryant J, Gallo RC, Lewis GK & Reitz M (2004) HIV-1 transgenic rats develop T cell abnormalities. Virology 321: 111-119.
39. Simonet WS, Lacey DL, Dunstan CR et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319.
40. Stone B, Dockrell D, Bowman C & McCloskey E (2010) HIV and bone disease. Arch Biochem Biophys 503: 66-77.
41. Takahashi N, Mundy GR & Roodman GD (1986) Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells. J Immunol 137: 3544-3549.
42. Takayanagi H, Ogasawara K, Hida S et al. (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408: 600-605.
43. Takayanagi H, Kim S, Koga T et al. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3: 889-901.
44. Takayanagi H, Sato K, Takaoka A & Taniguchi T (2005) Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 208: 181-193.
45. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL & Yarasheski KE (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14: F63-F67.
46. Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289: 1504-1508.
47. Triant VA, Brown TT, Lee H & Grinspoon SK (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93: 3499-3504.
48. van't Hof RJ & Ralston SH (1997) Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res 12: 1797-1804.
49. Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, Ofotokun I & Weitzmann MN (2010) Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. P Natl Acad Sci USA, 107: 13848-13853.
50. Wada T, Nakashima T, Hiroshi N & Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12: 17-25.
51. Weitzmann MN & Pacifici R (2007) T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann NY Acad Sci 1116: 360-375.
52. Womack JA, Goulet JL, Gibert C et al. (2011) Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 6: e17217.
53. Wong BR, Rho J, Arron J et al. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272: 25190-25194.
54. Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM & Choi Y (1998) The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J Biol Chem 273: 28355-28359.
55. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC & O'Brien CA (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17: 1235-1241.
56. Yadav A, Pati S, Nyugen A, Barabitskaja O, Mondal P, Anderson M, Gallo RC, Huso DL & Reid W (2006) HIV-1 transgenic rat CD4+ T cells develop decreased CD28 responsiveness and suboptimal Lck tyrosine dephosphorylation following activation. Virology 353: 357-365.
57. Yadav A, Fitzgerald P, Sajadi MM, Gilliam B, Lafferty MK, Redfield R & Reid W (2009) Increased expression of suppressor of cytokine signaling-1 (SOCS-1): a mechanism for dysregulated T helper-1 responses in HIV-1 disease. Virology 385: 126-133.
58. Yasuda H, Shima N, Nakagawa N et al. (1998a) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337.
59. Yasuda H, Shima N, Nakagawa N et al. (1998b) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. P Natl Acad Sci USA 95: 3597-3602.
60. Yin MT, McMahon DJ, Ferris DC et al. (2010) Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 95: 620-629.
61. Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, Manandhar M, Addesso V & Shane E (2005) Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 16: 1345-1352.
62. Young B, Dao CN, Buchacz K, Baker R & Brooks JT (2011) Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 52: 1061-1068.
63. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A & Abu-Amer Y (2001) Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276: 563-568.